ATP7A and cancer: Different strategies have been followed over the years to develop new ligands to target melanocortin receptors, leading to the development of peptide analogs, small molecules, and other innovative strategies including nano-delivery systems,167 antibody-based melanocortin agonism,175 targeted radiotherapies utilizing MC1 agonism to direct the drug to the target cancer cell176 (NCT05496686) or theranostics precision delivery technologies using MC1 agonism-based imaging to guide radiotherapy177 (NCT05655312).